Is retroelement-based gene editing a safer alternative to CRISPR-Cas approaches?

In a Perspective, Stephen Tang and Samuel Sternberg discuss retroelement-based gene editing as a safer alternative to CRISPR-Cas approaches.

Roche says its Carmot-acquired obesity pill is effective in early study

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 12, 2024

AB-1003 by Asklepios BioPharmaceutical for Limb-Girdle Muscular Dystrophy: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

February 16, 2024

Study finds link between low food security and metabolic syndrome in reproductive-aged Latinx females

Not having reliable access to food has a significant relationship with metabolic syndrome, a condition that increases risk for diseases such as diabetes and heart

June 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.